Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.
Breast Cancer Research Centre-Western Australia, Perth, WA, Australia. Electronic address: arlenechan@me.com.
Arlene
A
Chan
International Drug Development Institute, San Francisco, CA; I-BioStat, Hasselt University, Belgium.
Marc
M
Buyse
Puma Biotechnology Inc, Los Angeles, CA, USA.
Bin
B
Yao
D001943:Breast Neoplasms; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab